JPRN-UMIN000004406已完成2 期
ow dose estramustine phosphate against castration-resistant prostate cancer: phase II study - Low dose EMP against CRPC
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) Patients who have had estramustine phosphate therapy (including other estrogen-based hormone therapy) 2) Patients with malignancy within 5 years except carcinoma in situ or other malignancies limited within visceral mucosa 3) History of phlebitis, pulmonary embolism, intracranial infarction and coronary diseases 4) History of severe heart disease and renal diseases 5) Patients with active peptic ulcer 6) Psychiatric illness that makes it undesirable for the subject to participate in the trial 7) Evidence of any other significant disorder that make it undesirable for enrollment
研究者
相似试验
尚未招募
不适用
Medical management of refractory mastalgiaCTRI/2021/01/030359All India Institute of Medical Sciences Delhi
已完成
不适用
Treatment of non-responsive breast pain.CTRI/2017/12/010745Intra mural research grant10
进行中（未招募）
1 期
Repeated doses of misoprostol for medical treatment of intact miscarriageIntact miscarriage which has not been expelled from the body (missed abortion)EUCTR2011-001505-26-SEKarolinska Institutet899,991
进行中（未招募）
1 期
EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT.Women with confirmed high grade serous or endometrial epithelial ovarian cancer.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000693-30-ITENTE OSPEDALIERO OSPEDALI GALLIERA468
已完成
不适用
Clinical study on the efficacy and safety of EstroG-100J for menopausal symptoms: randomized double-blinded controlled studyJPRN-UMIN000015967Tsukuba International Clinical Pharmacology Clinic60